{"id":5337,"date":"2022-11-26T12:55:52","date_gmt":"2022-11-26T12:55:52","guid":{"rendered":"https:\/\/enews.sotout.com\/fda-approves-most-expensive-drug-ever-a-3-5-million-per-dose-gene-therapy-for-hemophilia-b\/"},"modified":"2022-11-26T12:55:52","modified_gmt":"2022-11-26T12:55:52","slug":"fda-approves-most-expensive-drug-ever-a-3-5-million-per-dose-gene-therapy-for-hemophilia-b","status":"publish","type":"post","link":"https:\/\/farratanews.online\/fda-approves-most-expensive-drug-ever-a-3-5-million-per-dose-gene-therapy-for-hemophilia-b\/","title":{"rendered":"FDA approves most expensive drug ever, a $3.5 million-per-dose gene therapy for hemophilia B"},"content":{"rendered":"

[ad_1]\n<\/p>\n

\n

Washington \u2014<\/em>\u00a0U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the genetic disorder which primarily affects men. <\/p>\n

Currently, patients receive frequent, expensive IVs of a protein that helps blood clot and prevent bleeding.<\/p>\n

\"Inside<\/span>
Signage for CSL Behring, a unit of CSL Ltd., is displayed at one of the company’s plants in Melbourne, Australia, in a July 2, 2014 file photo.<\/span><\/p>\n

<\/p>\n

Carla Gottgens\/Bloomberg via Getty<\/p>\n

<\/span>
\n <\/figcaption><\/figure>\n

Drugmaker CSL Behring, based in Pennsylvania, announced the $3.5 million price tag shortly after the FDA approval, saying its drug would ultimately reduce health care costs because patients would have fewer bleeding incidents and need fewer clotting treatments.<\/p>\n